Health & Nutrition

bg
Hims & Hers CEO says FTC lawsuit misunderstands how the company works

Hims & Hers CEO says FTC lawsuit misunderstands how the...

Hims & Hers CEO Andrew Dudum spoke to CNBC about the FTC's lawsuit against the...

bg
Nuts, Meat, and the Flaw in Nutrition Studies

Nuts, Meat, and the Flaw in Nutrition Studies

Do people who eat nuts live longer simply because they replace protein from animals...

bg
The startup using AI to help rare disease families develop custom treatments

The startup using AI to help rare disease families develop...

Nome uses AI and drug-development expertise to help rare disease families turn genetic...

bg
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs

Court rules companies can't import Gilead medications from...

A U.S. appeals court has ruled in favor of Gilead Sciences against companies known...

bg
Micromorts: Putting Risk Into Perspective

Micromorts: Putting Risk Into Perspective

A micromort, a unit for comparing and communicating risk to patients, is equivalent...

bg
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'

Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition...

Novo Nordisk CEO defended the company's decision to sue rival Eli Lilly over its...

bg
Trump administration ends Medicaid, CHIP funding for gender-affirming care for children

Trump administration ends Medicaid, CHIP funding for gender-affirming...

Federal dollars in the two health insurance programs would not go toward gender-affirming...

bg
We're lifting our price target on Cardinal Health after issuing rosy profit guidance

We're lifting our price target on Cardinal Health after...

The quarter wasn't totally clean, but strong profitability matters the most.

bg
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences

Trump wants to split the MMR vaccine. Experts say that's...

Doctors and other experts say that splitting the measles, mumps and rubella shot...

bg
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Jazz Pharmaceuticals to acquire Actio Biosciences for $820...

Jazz Pharmaceuticals will acquire Actio Biosciences, Inc., a deal that expands Jazz's...